Polygenic Background Modifies Risk of Coronary Artery Disease Among Individuals With Heterozygous Familial Hypercholesterolemia
Open Access
- 28 October 2023
- journal article
- research article
- Published by Elsevier in JACC: Advances
- Vol. 2 (9) , 100662
Abstract
No abstract availableKeywords
Funding Information
- National Human Genome Research Institute
- Eli and Edythe L Broad Institute of Harvard and MIT
This publication has 37 references indexed in Scilit:
- Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutationsNature Genetics, 2018
- Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapyJournal of Clinical Lipidology, 2018
- Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention SettingCirculation, 2017
- Statins in Familial HypercholesterolemiaJACC, 2016
- Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe HypercholesterolemiaJACC, 2016
- Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemiaAtherosclerosis, 2016
- Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217European Heart Journal, 2016
- Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trialsThe Lancet, 2015
- Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriersAtherosclerosis, 2014
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyEuropean Heart Journal, 2013